Clinical TrialPTSDMDMARecruiting

Effectiveness Of Psychedelic Therapy for Post Traumatic Stress Disorder (PTSD)

This interventional trial (n=30) will assess the efficacy and safety of MDMA-assisted psychotherapy for PTSD with 2–3 oral MDMA medicine days (120 mg + 60 mg top-up typical) alongside preparatory and integration psychotherapy.

Target Enrollment
30 participants
Study Type
Phase IV interventional
Design
Non-randomized

Detailed Description

Open-label, non-randomised, single-group study of MDMA-assisted psychotherapy for PTSD. Participants receive three preparatory 1‑hour sessions, 2–3 medicine days (6–7 hours each) with supportive, client-centred psychotherapy during dosing, and sets of integration sessions after each medicine day.

MDMA is administered orally in capsules by the treating psychiatrist; typical dosing follows MAPS protocols (120 mg with 60 mg top-up at ~2 hours; 80 mg + 40 mg top-up if needed). Adverse events are recorded and reported to HREC and the TGA; psychometric measures administered pre- and post-treatment.

Study Protocol

Preparation

3 sessions
60 min each

Dosing

3 sessions
420 min each

Integration

9 sessions
60 min each

Therapeutic Protocol

support

Study Arms & Interventions

MDMA therapy

experimental

Open-label, single-group MDMA-assisted psychotherapy with 2–3 medicine days interspersed with preparation and integration sessions.

Interventions

  • MDMA120 mg
    via Oralsingle dose per medicine day3 doses total

    Typical regimen 120 mg with 60 mg top-up at ~2 hours; lower option 80 mg + 40 mg top-up if not tolerated; dosing tailored by treating psychiatrist.

Participants

Ages
1865
Sexes
Male & Female

Inclusion Criteria

  • Must suffer from: Post Traumatic Stress Disorder

Exclusion Criteria

  • (1) Is not able to give adequate informed consent, or is under 18 or over 65 years old.
  • (2) Has uncontrolled hypertension or unstable diabetes.
  • (3) Has a marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 ms corrected by Bazett's formula).
  • (4) Has a history of additional risk factors for Torsade de pointes (e.g. heart failure, hypokalemia, family history of Long QT Syndrome).
  • (5) Has evidence or history of significant medical disorders e.g. epilepsy, stroke, unstable cardiovascular disease.
  • (6) Has symptomatic liver disease.
  • (7) Has a history of hyponatremia or hyperthermia.
  • (8) Weighs less than 48 kg.
  • (9) Is pregnant or nursing or is of childbearing age and is not practicing an effective means of birth control.
  • (10) Is currently abusing illegal drugs

Study Details

  • Status
    Recruiting
  • Phase
    Phase IV
  • Type
    interventional
  • Design
    Non-randomized
  • Target Enrollment30 participants
  • Timeline
    Start: 2023-12-04
    End: 2029-01-05
  • Compound
  • Topic

Locations

Unknown facilityAustralia

Your Library